var data={"title":"Gadofosveset: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gadofosveset: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/332570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gadofosveset-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gadofosveset: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50133501\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is requiring a new class warning, new Medication Guide, and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) regarding gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. However, because gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, the FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium retention, including those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. Although providers should minimize repeated GBCA imaging studies when possible, particularly closely spaced MRI studies, necessary GBCA MRI scans should not be avoided or deferred. Health care providers should ensure that patients carefully read the new Medication Guide before receiving a GBCA.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm&amp;token=Do7F8mUMHZ5/s1VO2ToSVQc0FIvxuJct8s2XQAmrP6Zclph1jTE4ohbEGIUswzhaMGIPSHysMdF12NhZ7JwyN2R2Gou2JaOgN/abp607dqC+GD0vx8r77GARzw9XI5at9GGki/68NHngWSah5+Qw3g==&amp;TOPIC_ID=8833\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents for MRI Safety Review</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA identified no evidence to date that gadolinium retention in the brain from any of the gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) is harmful, including GBCAs associated with higher retention of gadolinium, and therefore, restricting GBCA use is not warranted at this time. All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. The FDA will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future. Health care providers should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs. Retention of gadolinium affects only GBCAs, and does not apply to other types of scanning agents used for other imaging procedures, such as those that are iodine-based or radioisotopes.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=A+6oUwz5nYUZc3lEr1kP7BtLKnUrs6ODZsjcPV9KMyX4JnZOaUZ4v4WHkLmi0EKWvCCQ6RRR7uNYUokCfgeVc768Ba4J+HWDjLlRBCiBxtRZyZ58s7DOgXBX5msP35tg66ICqZf/qPRDl03GsgPnru8Lm2GCbUta4wNEC7od5KHrTCF6F4YU6ugBKJqroXAu&amp;TOPIC_ID=8833\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10117337\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrogenic systemic fibrosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with impaired elimination of the drugs. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with noncontrast-enhanced magnetic resonance imaging (MRI) or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk for NSF appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute per 1.73 m<sup>2</sup>) or acute kidney injury.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk of chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">For patients at highest risk for NSF, do not exceed the recommended gadofosveset dose. Allow a sufficient period of time for elimination of the drug from the body prior to readministration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10117338\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ablavar [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219405\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent;</li>\n      <li>\n        Gadolinium-Containing Contrast Agent;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Low Osmolality);</li>\n      <li>\n        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219558\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;\">\n      <b>Angiography imaging:</b> IV: 0.03 mmol/kg (0.12 mL/kg).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990348\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &ge;60 mL/kg/m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &lt;60 mL/kg/m<sup>2</sup>: 0.01 to 0.02 mmol/kg; use with caution. Risk for NSF development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first to third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987719\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Limited data suggest pharmacokinetics of gadofosveset in patients with hepatic disease do not differ substantially.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219559\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219567\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ablavar: 244 mg/mL (10 mL [DSC], 15 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219403\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219562\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as an intravenous bolus injection over a period up to 30 seconds through a dedicated IV line separate from other medications. Flush line with 25-30 mL NS after administration to ensure complete injection of medium. Imaging should be completed within 1 hour of injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219407\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Angiography imaging:</b> Contrast medium agent used in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219400\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vasovist [Hungary, Turkey] may be confused with Gadavist brand name for gadobutrol [U.S.]; Gadovist brand name for gadobutrol [Canada and multiple international markets]; Magnevist brand name for gadopentetate dimeglumine [U.S., Canada, and multiple international markets] </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219416\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasodilatation (3%), hypertension (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4%), paresthesia (3%), burning sensation (2%), dizziness (1%), sensation of cold (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (4%), dysgeusia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bruising at injection site (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anaphylactoid reaction, anaphylaxis, nephrogenic systemic fibrosis (NSF/NFD), prolonged Q-T interval on ECG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219412\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of prior hypersensitivity to any gadolinium-based contrast agent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219413\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>).</b> The risk appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, chronic hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT<sub>c</sub> prolongation: Rare cases of QT<sub>c</sub> prolongation have been observed with gadofosveset use. Data from pooled safety studies have demonstrated that the administration of gadofosveset resulted in minimal changes to the QT<sub>c</sub> interval as compared to placebo (means of 2.8 msec and 3.2 msec respectively). Consider baseline and follow up ECG in patients at increased risk of arrhythmias due to QT<sub>c</sub> prolongation (eg, underlying cardiac disease, concurrent medications). Patients should be monitored for at least 1 hour after the administration of gadofosveset.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of other gadolinium agents, generally within 48 hours following administration. Dosage reductions may be necessary. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299378\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219542\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8833&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10117339\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219408\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Gadnolinium-based contrast agents cross the placenta; in general, their use in pregnant women is controversial (ACOG 2016). Use should be avoided unless critical for the care of the mother or fetus, and it is not prudent to wait until after pregnancy. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219411\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Gadnolinium-based contrast agents are excreted into breast milk (ACR 2015). The manufacturer does not recommend use in breast-feeding women unless diagnostic imaging is essential and cannot be obtained by noncontrast MRA (consider the long half-life). Because of the low expected excretion into breast milk and the low absorption from an infant&rsquo;s GI tract, other sources note breast-feeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breast-feeding can pump and store milk prior to the procedure and abstain from breast-feeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219565\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline ECG if risk factors for QT<sub>c</sub> prolongation/torsade de pointes; baseline electrolytes (including potassium, calcium and magnesium); screen for renal impairment (all patients); baseline renal function in patients at risk of NSF and follow-up evaluation with renal dysfunction; signs of hypersensitivity (during and for several hours after procedure); short- and long-term monitoring of signs and symptoms of NSF/NFD (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219546\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gadofosveset is a gadolinium-containing paramagnetic agent that reversibly binds to albumin in the plasma. Exposure to an external magnetic field induces a large local magnetic field in exposed blood vessels. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device. The binding of gadofosveset to albumin prolongs the period of time gadofosveset resides intravascularly, enhances T1 relaxivity up to 10 times greater than nonprotein bound gadolinium chelates and provides a longer imaging window. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5219548\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 5 to 7 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 148 &plusmn; 16 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 80% to 87% (predominantly to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Negligible</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 16.3 &plusmn; 2.6 hours; moderate renal impairment: 49 hours; severe renal impairment: 70 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (79% to 94% as unchanged drug); feces (~5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196083\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: Clearance decreases substantially as renal function decreases. AUC increased 1.75-fold in patients with moderate (CrCl 30 to 50 mL/minute) and 2.25-fold in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324146\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ablavar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">244 mg/mL (10 mL): $145.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038898\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vasovist (AT, CH, CZ, DE, DK, EE, GR, HN, IE, NL, NO, PT, SE, SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ablavar (gadofosveset trisodium) [pescribing information]. North Billerica, MA: Lantheus; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caravan P, Cloutier NJ, Greenfield MT, et al, &ldquo;The Interaction of MS-325 With Human Serum Albumin and Its Effect on Proton Relaxation Rates,&rdquo; <i>J Am Chem Soc</i>, 2002, 124(12): 3152-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/11902904/pubmed\" target=\"_blank\" id=\"11902904\">11902904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Expert Panel on MR Safety, &quot;ACR Guidance Document on MR Safe Practices: 2013,&quot; <i>J Magn Reson Imaging</i>, 2013, 37(3):501-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/23345200/pubmed\" target=\"_blank\" id=\"23345200\">23345200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joffe P, Thomsen HS, and Meusel M, &quot;Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,&quot; <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/9653466/pubmed\" target=\"_blank\" id=\"9653466\">9653466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuo PH, Kanal E, Abu-Alfa AK, et al, &quot;Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,&quot; <i>Radiology</i>, 2007, 242(3):647-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/17213364/pubmed\" target=\"_blank\" id=\"17213364\">17213364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauffer RB, Parmelee DJ, Dunham SU, et al, &ldquo;MS-325: Albumin-Targeted Contrast Agent for MR Angiography,&rdquo; <i>Radiology</i>, 1998, 207(2): 529-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/9577506/pubmed\" target=\"_blank\" id=\"9577506\">9577506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo; <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/11350296/pubmed\" target=\"_blank\" id=\"11350296\">11350296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perreault P, Edelman MA, Baum RA, et al, &ldquo;MR Angiography with Gadofosveset Trisodium for Peripheral Vascular Disease: Phase II Trial,&rdquo; <i>Radiology</i>, 2003, 229(3):811-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/14593194/pubmed\" target=\"_blank\" id=\"14593194\">14593194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shamsi K, Yucel EK, and Chamberlin P, &ldquo;A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose,&rdquo; <i>Invest Radiol</i>, 2006, 41(11): 822-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadofosveset-drug-information/abstract-text/17035873/pubmed\" target=\"_blank\" id=\"17035873\">17035873</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8833 Version 95.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50133501\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10117337\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10117338\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5219405\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5219558\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990348\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987719\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5219559\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5219567\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5219403\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5219562\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5219407\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5219400\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5219416\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5219412\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5219413\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299378\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5219542\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F10117339\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5219408\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5219411\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5219565\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5219546\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5219548\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196083\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324146\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038898\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8833|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gadofosveset-patient-drug-information\" class=\"drug drug_patient\">Gadofosveset: Patient drug information</a></li></ul></div></div>","javascript":null}